Muhammad Hasnawi Haddani

Muhammad Hasnawi Haddani

Auto-generated profile, based on publicly available information

Muhammad Hasnawi Haddani

Department of Neurology, Faculty of Medicine, Universitas Sriwijaya, Mohammad Hoesin Hospital, Palembang, Indonesia

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2018 in Asian Journal of Medical Sciences
Verified
Journal Article
Open access
PDF file
MHManfaluthy Hakim
Manfaluthy Hakim
NKNani Kurniani
Nani Kurniani
RPRizaldy Taslim Pinzon
Rizaldy Taslim Pinzon
DTDodik Tugasworo
Dodik Tugasworo
MBMudjiani Basuki
Mudjiani Basuki
AWAudry Devisanty Wuysang
Audry Devisanty Wuysang
Background: Peripheral neuropathy is a common condition which can have a significant impact on quality of life. It occurs as a component of several common and rare diseases or can be idiopathic and can present with various symptoms.Aims and Objectives: This study is aimed at evaluating the effectiveness and safety of the fixed dose combination of vitamin B1, B6 and B12in mild to moderate peripheral neuropathy of various etiologies in the Indonesian population.Materials and Methods: This was a prospective, open label, multi-center, single arm observational study (Indonesian Clinical Trial Registry No: INA-KPA0DYA). A total of 411 subjects with mild to moderate peripheral neuropathy of various etiologies, who met the eligibility criteria, were included in the study. A subject was considered to have “completed” the study if the study procedures, up to Visit 3 (one month of treatment) were accomplished. Procedural results and 12-week clinical outcomes are reported.Results: Treatment with combination of vitamin B1, B6 and B12 in subjects with symptoms of PN showed significant improvement in overall Total Symptom Score (TSS), within 14 days. The treatment also successfully reduced individual components of TSS from baseline to Visit 5. A significant percentage reduction was also observed for all the Visual Analogue Scale (VAS) parameters at the end of 12 weeks, while the Quality of Life (QoL) scores increased from baseline to the end of treatment.Conclusions: The fixed dose combination of vitamin B1, B6 and B12 was effective and welltolerated in subjects with mild to moderate peripheral neuropathy, of various etiologies.Asian Journal of Medical Sciences Vol.9(1) 2018 32-40

31 March 2026 in NeuroRegulation
Verified
Journal Article
Open access
RNRini Nindela
Rini Nindela
YFYohanes Febrianto
Yohanes Febrianto
YYYusril Yusril
Yusril Yusril
MHMuhammad Hasnawi Haddani
Muhammad Hasnawi Haddani
SHSri Handayani
Sri Handayani
MSMgs. Irsan Saleh
Mgs. Irsan Saleh
Background. Poststroke cognitive impairment (PSCI) involves cognitive deficits emerging within 3 months after stroke. Quantitative EEG (qEEG) in PSCI typically shows changes in relative power, delta-alpha ratio, and peak alpha frequency. Neurofeedback training (NFT) is a promising intervention to improve cognitive function and qEEG patterns, though findings remain inconsistent. Nonetheless, even brief NFT interventions may yield meaningful benefits. Methods. This study assessed the effectiveness of five individualized qEEG-guided NFT sessions (30 min each) in 24 PSCI patients, focusing on changes in MoCA-INA scores and qEEG parameters. Results. NFT significantly improved MoCA-INA scores (Z = −4.106, p < .001, effect size = 0.839), particularly in visuospatial/executive and delayed recall domains, with sustained effects 1 month later. QEEG analysis revealed increased temporal alpha (t = −1.875, p = .037, effect size = 0.23) and parietal beta relative power (t = −1.827, p = .040, effect size = 0.11). Greater cognitive gains were observed in patients aged ≤60 years. Conclusion. These findings support the clinical utility of short-term, qEEG-guided NFT in improving cognitive outcomes and modulating neural activity in PSCI patients. The sustained benefits observed suggest potential for long-term therapeutic impact.